Robert D. Murray, MD PhD

Department of Endocrinology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom

Disclosure information not submitted.

Presentation(s):

• SUN-464 - Cross-Sectional Assessment of the Health Status in Adults with CAH in the UK and Ireland - Cahase2

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• ORF28-05 - Effect of CAM2029 on Long-Term Biochemical and Symptom Control in Patients with Acromegaly and IGF-I ≤2×ULN According to Prior Injectable Somatostatin Receptor Ligand Dose: Results from ACROINNOVA 2

  Sunday, June 14, 2026
  2:15 PM - 2:30 PM CT

• MON-036 - Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT